Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Literature
1.
Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to Moderate Muscular Symptoms with High Dosage Statin Therapy in Hyperlipidemic Patients-the PRIMO Study. Cardiovasc Drugs Ther. 2005;19:402–14.CrossRef
2.
Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction (EPlerenone’s neuroHormonal Efficacy and SUrvival Study). Cardiovasc Drugs Ther. 2001;15:79–87.
3.
Smith C, Davidson S, Lim S, Simpkin J, Hothersall J, Yellon D. Necrostatin: a Potentially Novel Cardioprotective Agent? Cardiovasc Drugs Ther. 2007;21:227–33.CrossRef
4.
Burke J, Dennis E. Phospholipase A2 Biochemistry. Cardiovasc Drugs Ther. 2009;23:49–59.CrossRef
5.
Mitra S, Goyal T, Mehta J. Oxidized LDL, LOX-1 and Atherosclerosis. Cardiovasc Drugs Ther. 2011;25:419–29.CrossRef
6.
Mehta J, Khaidakov M, Hermonat P, Mitra S, Wang X, Novelli G. LOX-1: a New Target for Therapy for Cardiovascular Diseases. Cardiovasc Drugs Ther. 2011;25:495–500.CrossRef
7.
Tarkin J, Kaski JC. Update on Pharmacological Agents for Management of Chronic Stable Angina : Introduction. Cardiovasc Drugs Ther. 2016;30:339–40.CrossRef
8.
Kitakaze M. How to Mediate Cardioprotection in Ischemic Hearts-Accumulated Evidence of Basic Research Should Translate to Clinical Medicine. Cardiovasc Drugs Ther. 2010;24:217–23.CrossRef
9.
Davidson SM. Editorial to: Building a Bridge to the Future of Cardiovascular Drugs and Therapy. Cardiovasc Drugs Ther. 2017;31:51–2.CrossRef
10.
Mehta JL. Women and Heart Disease; a Focus Issue. Cardiovasc Drugs Ther. 2015;29:317–8.CrossRef
11.
Chen YE. Editorial: the Yin and Yang of Perivascular Adipose Tissue in Vascular Disease. Cardiovasc Drugs Ther. 2018;32:477–9.CrossRef
12.
Remme CA, Wilde A. Late Sodium Current Inhibition in Acquired and Inherited Ventricular (Dys)function and Arrhythmias. Cardiovasc Drugs Ther. 2013;27:91–103.CrossRef
13.
Rosenson R, Koenig W. Special Issue on Biological Causality: When Experimental Models and Human Genetics Conflict. Mendelian Randomization Analysis for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. Cardiovasc Drugs Ther. 2016;30(1):65–74.CrossRef
14.
Rosenson R. Special Section: Phospholipase, Inflammation and Cardiovascular Disease. Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2009;23:93–101.CrossRef
Metadata
Title
My Last Issue—a Farewell to Cardiovascular Drugs and Therapy
Author
Willem J. Remme
Publication date
01-12-2019
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 6/2019
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-019-06928-3

Other articles of this Issue 6/2019

Cardiovascular Drugs and Therapy 6/2019 Go to the issue

LETTER TO THE EDITOR

Prediabetes with Hypertension and Dyslipidemia: Are They Triad of Future Cardiovascular Risk?

REVIEW ARTICLE

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives

Review Article

Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management

SHORT COMMUNICATION

The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart

ORIGINAL ARTICLE

Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart Failure

REVIEW ARTICLE

Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits